Shizuru Judith Anne
SEC Form 4 insider trading activity
Shizuru Judith Anne has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2025. 1 of those filings fall inside the rolling window. Most recent filing: Sep 24, 2025.
On the most recent filing, Shizuru Judith Anne is listed as Director at Jasper Therapeutics, Inc. Inside the rolling window, Shizuru Judith Anne reported 1 open-market purchase totaling $100K in JSPR and no open-market sales.
Companies traded
Other insiders at JSPR
Insider Buying
$100K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Shizuru Judith Anne made?
Shizuru Judith Anne has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2025.
Which companies does Shizuru Judith Anne trade?
Shizuru Judith Anne has filed SEC Form 4 disclosures for 1 company, including JSPR.
When was Shizuru Judith Anne's most recent SEC Form 4 filing?
Shizuru Judith Anne's most recent SEC Form 4 filing on Tracefour is dated Sep 24, 2025.
What is Shizuru Judith Anne's total buy and sell value in the current window?
Inside the rolling retention window, Shizuru Judith Anne bought $100K and sold $0 based on SEC Form 4 filings.
What was Shizuru Judith Anne's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 41,000 JSPR shares on 2025-09-22, worth $100K, per SEC Form 4 filings.